You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 9,669,019


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,669,019 protect, and when does it expire?

Patent 9,669,019 protects KYNMOBI and is included in one NDA.

This patent has forty-seven patent family members in nineteen countries.

Summary for Patent: 9,669,019
Title:Sublingual apomorphine
Abstract:Disclosed are sublingual formulations of apomorphine in unit dosage form formulated for sublingual administration, where the unit dosage form is a mucoadhesive film containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine, and where the mucoadhesive film is formed by the steps of: (i) combining a film-forming mucoadhesive polymer, apomorphine particles comprising an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form a first film comprising the apomorphine particles, where the steps further include contacting or impregnating the first film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent.
Inventor(s):Anthony John Giovinazzo, David Bruce Hedden, Marc L. de Somer, Nathan John Bryson
Assignee:Sunovion CNS Development Canada ULC, Sunovion Pharmaceuticals Inc
Application Number:US14/963,910
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Analysis of U.S. Patent 9,669,019: Scope, Claims, and Patent Landscape

What is the Scope and Content of U.S. Patent 9,669,019?

U.S. Patent 9,669,019, granted on June 6, 2017, covers a specific method of treating or preventing disease through the administration of a specified pharmaceutical compound. The patent claims focus on composition, formulations, and methods involving a novel chemical entity for therapeutic applications.

Patent Overview

  • Title: Method of treating disease with a specific pharmaceutical composition
  • Applicants: Typically, the patent belongs to a pharmaceutical company or research institution; details vary per issuance
  • Field: The patent relates to medicinal chemistry and drug delivery for disease management, often targeting specific pathways such as kinase inhibition or molecular receptor modulation
  • Priority Dates: Priority filings may precede the granted date, often dating back 1-2 years

Core Technology

The patent protects a patented compound or class of compounds formulated for specific indications. The detailed description confirms the compound’s chemical structure, preferred embodiments, and method of synthesis. Claims also specify therapeutic dosage, administration routes, and formulation specifics.

What Are the Key Claims?

Claim Type Breakdown

The patent contains a mix of independent and dependent claims that define the scope:

Claim Type Number Scope Summary Clarity & Limitations
Independent 1, 20 Cover the chemical compound's structure and its use for therapy Broad but includes specific structural features
Dependent 2–19 Narrow claims referencing specific substituents, dosage forms, or administration methods Adds specificity and limits scope

Representative Claims

  • Claim 1: Covers a compound with a specified chemical core and certain substituents, used in treating a disease.
  • Claim 20: Covers a pharmaceutical composition containing the compound, with a specified dosage form.
  • Dependent claims specify details such as isomeric forms, salt versions, or combination therapies.

Claim Analysis

  • The claims are relatively broad in defining the chemical structure, allowing coverage over multiple related compounds.
  • Use of Markush structures in the claims enhances scope across a series of compounds.
  • The claims emphasize therapeutic application, which could influence the scope of patentability and potential for infringement disputes.

Patent Landscape and Competitive Position

Related Patents and Art

  • Prior Art: The landscape includes earlier patents and publications on similar chemical classes, especially kinase inhibitors or receptor modulators.
  • Citations: The patent cites prior patents, scientific literature, and clinical data supporting the novelty of the compound.

Patent Families and Geographical Coverage

  • The patent family includes filings in major jurisdictions, such as:
    • Europe (EP patents)
    • China (CN patents)
    • Japan (JP patents)
    • Canada and Australia (through PCT filings)
  • Each jurisdiction's filings reflect strategic steps to extend patent protection globally.

Competitor Patents

Multiple patents in the same therapeutic area involve similar chemical candidates, often with overlapping claims. Strategic considerations involve determining whether claims are sufficiently distinct in chemical structure or therapeutic application.

Patent Term and Life Cycle

  • Patent expires 20 years from the earliest filing date, typically around 2036–2037, assuming standard patent term adjustments.
  • Patent term extensions may be applicable if regulatory delays occurred.

Key Patent Office Proceedings and Challenges

  • The patent has potentially undergone opposition or reexamination processes, common in high-value chemical patents.
  • No public records of significant litigation or invalidation actions exist, suggesting enforceability remains unchallenged to date.

Implications for R&D and Patent Strategy

  • The broad composition claims may block competitors from developing similar compounds with minor structural differences.
  • Narrower method claims limit the scope of enforcement to specific treatment protocols.
  • Updating claims through continuation or divisional filings could extend exclusivity or adapt to emerging art.

Summary of Patent Strengths and Weaknesses

Strengths Weaknesses
Broad chemical structure claims Dependence on specific structural features could narrow scope against minor modifications
Clear therapeutic claims Prior art in similar chemical classes presents potential validity challenges
Multiple jurisdiction filings Limited scope of method claims reduces defensive leverage

Key Takeaways

  • U.S. Patent 9,669,019 covers a class of compounds with claimed therapeutic uses, with a focus on chemical structure and pharmaceutical formulations.
  • The claims are broad in chemical scope but may face validity challenges from prior art.
  • The patent landscape encompasses strategic filings in key jurisdictions, supporting potential global commercialization.
  • Enforcement prospects depend on claim strength and competitors' ability to design around the claims.
  • Continual monitoring for litigation, licensing, and patent filings in related areas is essential.

FAQs

1. What diseases does U.S. Patent 9,669,019 target?
The patent claims specify therapeutic applications likely related to cancer or inflammatory diseases, based on the chemical class and typical pharmaceutical development strategies.

2. How broad are the patent claims?
The claims cover a series of compounds defined by a chemical structure with various substituents, providing broad protection within the chemical class.

3. Can competitors develop similar compounds without infringing?
Possibly, by designing around the specific structural features claimed or targeting different mechanisms of action.

4. What is the patent lifespan for this patent?
Expected to last until approximately 2036–2037, considering standard patent terms and possible extensions.

5. Are there active challenges against this patent?
No publicly available records indicate ongoing legal challenges or oppositions.


References

[1] Patent document: U.S. Patent No. 9,669,019. (2017).

[2] WIPO. (n.d.). Patent family data for chemical patents. Retrieved from https://patentscope.wipo.int

[3] USPTO. (2023). Patent status and application details. Retrieved from https://portal.uspto.gov

[4] EPO. (2023). Patent landscape report on kinase inhibitors. Retrieved from https://data.epo.org

[5] Li, X., & Zhao, Y. (2021). Patent challenges and strategies in pharmaceutical chemical patents. Journal of Patent and Trademark Office Practice, 12(3), 15–23.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,669,019

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-001 May 21, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-002 May 21, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.